Becton, Dickinson and Company (BDX) Expected to Announce Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) will likely be announcing its Q2 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect Becton, Dickinson and Company to post earnings of $3.28 per share and revenue of $5.35 billion for the quarter. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.600 EPS.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, analysts expect Becton, Dickinson and Company to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $202.39 on Thursday. The firm’s 50 day moving average price is $219.31 and its 200-day moving average price is $227.78. The stock has a market capitalization of $58.11 billion, a PE ratio of 33.62, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $193.03 and a twelve month high of $251.99.

Becton, Dickinson and Company announced that its board has authorized a share repurchase program on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 10th were given a $1.04 dividend. The ex-dividend date was Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 2.06%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Richard Byrd sold 459 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the sale, the executive vice president now directly owns 6,952 shares of the company’s stock, valued at approximately $1,598,960. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 479 shares of the firm’s stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the sale, the executive vice president now directly owns 4,887 shares of the company’s stock, valued at $964,107.36. This represents a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,578 shares of company stock valued at $795,986. Insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

A hedge fund recently raised its stake in Becton, Dickinson and Company stock. Brighton Jones LLC raised its position in Becton, Dickinson and Company (NYSE:BDX) by 98.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,770 shares of the medical instruments supplier’s stock after acquiring an additional 877 shares during the quarter. Brighton Jones LLC’s holdings in Becton, Dickinson and Company were worth $401,000 at the end of the most recent quarter. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on BDX shares. Piper Sandler cut their price objective on Becton, Dickinson and Company from $280.00 to $260.00 and set an “overweight” rating on the stock in a research report on Wednesday. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 2nd. Finally, Barclays cut their price objective on Becton, Dickinson and Company from $279.00 to $261.00 and set an “overweight” rating for the company in a research report on Monday, April 7th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $272.86.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.